Danaher collaboration at ESCMID Global 2025 to transform the future of clinical microbiology
7 May 2025
At this year’s ESCMID Global 2025 conference, Beckman Coulter Microbiology and Cepheid made a powerful debut under a joint Danaher booth, marking a significant step in diagnostic innovation. Beckman Coulter Microbiology President, Christian Borjesson, welcomes Dr. Stephanie Mitchell to the team as Principal Scientist and Scientific Director. Together, they share their vision of integrating molecular diagnostics, phenotypical susceptibility testing, and immunodiagnostics to better serve clinicians and patients.
One pressing challenge in clinical microbiology is the demand to do more with fewer resources, impacting screening programs for multi drug-resistant organisms. This underscores the urgency of cross-functional collaborations — engaging governmental agencies, labs, diagnostics, and pharmaceutical companies to accelerate detection and response. A One Health perspective, bridging agriculture, environment, and veterinary sciences, will be crucial in combating global antimicrobial resistance.
This partnership marks a significant step forward in protecting public health through cutting-edge diagnostics and strategic collaboration. The future of microbiology is evolving, and Beckman Coulter is at the forefront of change.
This video was filmed at ESCMID Global 2025 in Vienna, Austria.
About the company
Beckman Coulter Diagnostics
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents approximately 78 percent of the company s 2007 annual revenue of $2.76 billion. For more information, visit www.beckmancoulter.com.
